Nephros Inc Stock Price, News & Analysis

Nephros (Nasdaq: NEPH) will file its third-quarter 2025 financial results on Thursday, November 6, 2025 after market close and will host a conference call the same day at 4:30 PM ET.

Participants can join via domestic dial 1 (844) 808-7106 or international dial 1 (412) 317-5285 and should ask to be joined into the Nephros conference call. An audio archive will be posted on the Nephros Investor Relations page shortly after the call.

A replay is available through November 13, 2025 by calling 1 (877) 344-7529 (U.S.) or 1 (412) 317-0088 (international) and entering replay access code 7475880.

Nephros (NASDAQ: NEPH) launched the 19-Series PFAS Filter on October 8, 2025, a point-of-use filter designed to reduce Total PFAS in potable water.

The filter is independently tested to NSF Standards 42 and 53, validated to reduce Total PFAS including PFOA and PFOS, and also reduces lead, asbestos, cysts, chlorine, taste, and odor. Product specs include a 3,145-gallon capacity and 1.63 GPM flow rate. Target customers include healthcare, daycares, education, foodservice, and manufacturing. Performance data is available on the product page.

Nephros (NASDAQ:NEPH), a water technology company, reported outstanding Q2 2025 financial results with significant growth and continued profitability. The company achieved net revenue of $4.4 million, marking a 36% increase year-over-year, and recorded its third consecutive profitable quarter with net income of $237,000.

Key highlights include a record-high programmatic sales performance, the largest dialysis filtration purchase order in company history, and all-time high active-site counts across all segments. The company's gross margin improved to 63%, up from 59% in Q2 2024, while maintaining a strong cash position of $5.1 million with no debt.

For the first half of 2025, Nephros reported net revenue of $9.3 million, up 37% year-over-year, with net income of $795,000 and Adjusted EBITDA of $1 million, demonstrating sustained growth and operational excellence.

Nephros (Nasdaq: NEPH), a water technology company specializing in filtration solutions for medical and commercial markets, has scheduled its second quarter 2025 financial results announcement for August 07, 2025 after market close.

The company will host a conference call at 4:30 PM ET on the same day. Investors can access the call through domestic (1-844-808-7106) or international (1-412-317-5285) lines. A replay will be available until August 15, 2025, using access code 6362809.

Nephros (Nasdaq: NEPH), a leading water technology company specializing in medical and commercial filtration solutions, has announced its participation in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11, 2024, at the New York Athletic Club in New York City.

CEO Robert Banks and CFO Judy Krandel will represent Nephros at the conference, conducting one-on-one and group meetings with investors and analysts throughout the day. The conference format is designed to connect emerging growth companies with institutional and individual investors.

Nephros reported Q3 2024 financial results with net revenue of $3.5 million, marking an 8% increase over Q2 2024 but a 6% decrease from Q3 2023. The company achieved its first profitable quarter with net income of $0.2 million, compared to a net loss of $0.2 million in Q3 2023. Gross margins improved to 61% from 59% year-over-year. Adjusted EBITDA reached $295,000, up from $11,000 in the same period last year. Cash position stood at $2.5 million as of September 30, 2024, down from $4.3 million at the end of 2023.

Nephros (Nasdaq: NEPH), a water technology company specializing in filtration solutions for healthcare and commercial markets, announced it will release its third-quarter 2024 financial results on Thursday, November 7, 2024, after market close. The company will host a conference call at 4:30pm ET the same day. Participants can join via domestic access (1-844-808-7106) or international access (1-412-317-5285). An audio archive will be available on the Nephros Investor Relations page, with replay access until November 14, 2024.

Nephros (Nasdaq: NEPH) has launched the HydraGuard 20" UltraFilter, expanding its filtration technology portfolio. The new filter offers higher-volume capacity and flow rate while removing bacteria, viruses, and endotoxins. This product enables Nephros to enter new markets, particularly medical device manufacturing and pharmaceutical production, supporting compliance with water quality standards like ANSI/AAMI ST108.

The filter builds upon existing HydraGuard technology, previously to dialysis water purification, and provides exceptional retention of microbiological contaminants through size exclusion, offering more reliable performance compared to charged membranes.

Nephros, Inc. (Nasdaq: NEPH), a leader in advanced filtration technology, has responded rapidly to the recent hurricanes Helene and Milton that devastated parts of the southeastern United States. The company provided important water filtration solutions to multiple healthcare and nursing care facilities affected by the storms, ensuring a safe water supply for patients and staff during recovery efforts.

Nephros has shipped a significant number of filters, responding after hours and delivering next day to both federal and local disaster response partners. Their solutions have been deployed across multiple states and facility types, including:

• Florida hospitals where Nephros in-line filters were previously installed
• North Carolina nursing and care facilities where point-of-use filters provided immediate protection against bacteria

The company's ability to act quickly in disaster response situations underscores its commitment to clean water access, offering an effective alternative to typical emergency water sources.